Navitor taps new board, SAB members; Sanofi, Regeneron post more promising data for Praluent; Nektar wins $40M milestone;

@FierceBiotech: ICYMI: Sanofi buys into Google's biotech future, pairing up in diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Just wondering how Valeant's reps plan to market brodalumab. Suicidal thinking? No worries, mate. Story | Follow @JohnCFierce

@DamianFierce: "Valeant is acquiring __________ for $__________, touting the drug's __________ despite serious concerns about ___________." | Follow @DamianFierce

> Cambridge, MA-based Navitor Pharmaceuticals tapped David Madden for the board. Michael Hall, professor at the Biozentrum of the University of Basel and the discoverer of the target of rapamycin (TOR) complexes, has joined the Navitor Scientific Advisory Board. Release

> AstraZeneca ($AZN) has handed a $40 million milestone payment to Nektar Therapeutics for the first commercial sales of Moventig in Germany. Report

> Sanofi ($SNY) and Regeneron ($REGN) have posted a fresh set of promising data for their newly approved cholesterol drug Praluent. Release

> Hemispherx ($HEB) says it won't pay out executive bonuses until it makes good on its manufacturing goals. Story

Medical Device News

@FierceMedDev: Exact Sciences wins CMS panel vote for Cologuard pricing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. Article | Follow @VarunSaxena2

@EmilyWFierce: Social media spin mistress @KimKardashian mops up Duchesnay's marketing mess. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Germany's coramaze receives $5M in Series A to develop transcatheter mitral valve repair device. Article

> CeQur reels in $100M for insulin infusion smart patch device. News

Pharma News

@FiercePharma: UPDATED: It's confirmed: 'No signal' of heart failure risk with Merck's Januvia. More | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: No change in CV risk for ACS patients on Sanofi's Lyxumia. Item | Follow @CarlyHFierce

> J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data. More

> ESC: AstraZeneca gets more backing for long-term Brilinta use. Article

Pharma Manufacturing News

> Three pharmaceutical company owners in India busted for distributing pseudoephedrine. Item

> Regis Technologies opens new facility for manufacturing highly potent APIs. Report

> Mega Lifesciences to expand in Indonesia on partnership with Sydna Farma. More

> AMRI, Saneca Pharma team to produce a range of opium-based APIs. Story

> Mayne Pharma to spend $65M on expansion of North Carolina facility. Article

Pharma Asia News

> Two dengue treatments slated for PhII in Singapore next year. Report

> Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications. Item

> Another recall by Indian drugmakers as U.S. FDA notes troubles. More

> Executive shakeup with Guilder out at Taiwan's TWi. Story

> Shanghai Pharmaceutical raises funds for online-to-offline sales push with eye on ethical products. Article

Drug Delivery News

> Surefire picks up FDA clearance for Precision cancer drug delivery tool. More

> MicroRNA specialist aims for $81M IPO amid market downturn. Report

> Teva makes only approved migraine patch available in the U.S. Story

> Intraoperative radiation therapy proving divisive among oncologists. Item

> Titan Pharma submits opioid addiction-fighting subdermal implant for FDA approval. Article

 
 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.